BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 26756229)

  • 1. Breast cancer subtypes: morphologic and biologic characterization.
    Masood S
    Womens Health (Lond); 2016 Jan; 12(1):103-19. PubMed ID: 26756229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials in the era of personalized oncology.
    Maitland ML; Schilsky RL
    CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy.
    Burstein HJ
    Am Soc Clin Oncol Educ Book; 2014; ():e1-3. PubMed ID: 24857085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision medicine in breast cancer.
    Naito Y; Urasaki T
    Chin Clin Oncol; 2018 Jun; 7(3):29. PubMed ID: 30056731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting].
    Gonçalves A; Moretta J; Eisinger F; Bertucci F
    Bull Cancer; 2013 Dec; 100(12):1295-310. PubMed ID: 24225763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized therapy in breast cancer.
    Marmé F; Schneeweiss A
    Onkologie; 2012; 35 Suppl 1():28-33. PubMed ID: 22286585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-Oncology in the Era of Personalized Medicine.
    Gwin WR; Disis ML; Ruiz-Garcia E
    Adv Exp Med Biol; 2019; 1168():117-129. PubMed ID: 31713168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
    Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
    PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience.
    Orucevic A; Chen J; McLoughlin JM; Heidel RE; Panella T; Bell J
    Breast J; 2015; 21(2):147-54. PubMed ID: 25600504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular classification of infiltrating breast cancer: toward personalized therapy.
    Trop I; LeBlanc SM; David J; Lalonde L; Tran-Thanh D; Labelle M; El Khoury MM
    Radiographics; 2014; 34(5):1178-95. PubMed ID: 25208275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
    Golan T; Milella M; Ackerstein A; Berger R
    J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma.
    Ni YB; Tsang JY; Chan SK; Tse GM
    Ann Surg Oncol; 2014 Sep; 21(9):2928-33. PubMed ID: 24743910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic heterogeneity in breast cancer: the road to personalized medicine?
    Baird RD; Caldas C
    BMC Med; 2013 Jun; 11():151. PubMed ID: 23800221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional MR Imaging Techniques in Oncology in the Era of Personalized Medicine.
    Benz MR; Vargas HA; Sala E
    Magn Reson Imaging Clin N Am; 2016 Feb; 24(1):1-10. PubMed ID: 26613872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer in the Elderly: Moving the Needle Toward Evidence-Based Personalized Oncology.
    Extermann M
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):718-720. PubMed ID: 28602406
    [No Abstract]   [Full Text] [Related]  

  • 18. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy.
    Norum JH; Andersen K; Sørlie T
    Br J Surg; 2014 Jul; 101(8):925-38. PubMed ID: 24849143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Future of Cancer Care: Are We Ready For Personalized Value?
    de Souza JA; Kelly C; Nabhan C
    J Natl Compr Canc Netw; 2015 Aug; 13(8):1049-51. PubMed ID: 26285249
    [No Abstract]   [Full Text] [Related]  

  • 20. Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
    Corey L; Valente A; Wade K
    Obstet Gynecol Clin North Am; 2019 Mar; 46(1):155-163. PubMed ID: 30683261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.